Meeting
2022 ASCO Annual Meeting
A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6.
Authors
Gerald Steven Falchook
Sarah Cannon Research Institute at HealthONE, Denver, CO
Gerald Steven Falchook , Manish R. Patel , Susanna Varkey Ulahannan , Daniela Maier , Susanne Hipp , Hisaya Azuma , David R. Spigel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04752215
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3175)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3175
Abstract #
TPS3175
Poster Bd #
154b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma.
First Author: Jiajian Liu
Poster
2023 ASCO Annual Meeting
A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.
First Author: Pei Shu
Poster
2022 ASCO Annual Meeting
A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).
First Author: Mehmet Akce
Poster
2018 ASCO Annual Meeting
A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer.
First Author: You Lu